Experimental stroke: Neurolysin back on stage

Journal of Neurochemistry

Volumn 129, Issue 1, 2014, Pages 1-3

  Checler, Frédéric ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; NEUROLYSIN;

BRAIN ISCHEMIA; CYTOSOL; EDITORIAL; EXPERIMENTAL STROKE; MIDDLE CEREBRAL ARTERY OCCLUSION; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; METALLOENDOPEPTIDASES; STROKE;

EID: 84897112981     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12635     Document Type: Editorial

References (12)

1. Checler F., Vincent J. P., and, Kitabgi P., (1986) Purification and characterization of a novel neurotensin degrading peptidase from rat brain synaptic membranes. J. Biol. Chem. 261, 11274-11281.
2. Dauch P., Vincent J. P., and, Checler F., (1991) Specific inhibition of endopeptidase 24.16 by dipeptides. Eur. J. Biochem. 202, 269-276.
3. Dauch P., Vincent J. P., and, Checler F., (1995) Molecular cloning and expression of rat brain endopeptidase 3.4.24.16. J. Biol. Chem. 270, 27266-27271.
4. Jiracek J., Yiotakis A., Vincent B., Checler F., and, Dive V., (1996) Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides. J. Biol. Chem. 271, 19606-19611.
5. John A., and, Tuszynski G., (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. 7, 14-23.
6. Mizutani S., Ishii M., Hattori A., Nomura S., Numaguchi Y., Tsujimoto M., Kobayshi H., Murohara T., and, Wright J. W., (2008) New insights into the importance of aminopeptidase A in hypertension. Heart Fail. Rev. 13, 273-284.
7. Rashid M., Wangler N., Yang L., Shah K., Arumagam T. V., Abbruscato T., and, Karamyan V., (2013) Functional up-regulation of endopeptidase neurolysin during post-acute and early recovery phase of experimental stroke in mouse brain. J. Neurochem, doi: 10.1111/jnc.12513. [E-pub ahead of print].
8. Rioli V., Kato A., Portaro F. C., et al,. (1998) Neuropeptide specificity and inhibition of recombinant isoforms of the endopeptidase 3.4.24.16 family: comparison with the related recombinant endopeptidase 3.4.24.15. Biochem. Biophys. Res. Commun. 250, 5-11.
9. Roques B. P, Fournié-Zaluski M. C,. and, Wurm M., (2012) Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat. Rev. Drug. Discov. 11, 292-310.
10. Vincent B., Beaudet A., Dauch P., Vincent J. P., and, Checler F., (1996) Distinct properties of neuronal and astrocytic endopeptidase 3.4.24.16: a study on differentiation, subcellular distribution and secretion processes. J. Neurosci. 16, 5049-5059.
11. Vincent B., Jiracek J., Noble F., Loog M., Roques B., Dive V., Vincent J. P., and, Checler F., (1997) Effect of a novel selective and potent phosphinic peptide inhibitor of endopeptidase 3.4.24.16 on neurotensin-induced analgesia and neuronal inactivation. Br. J. Pharmacol. 121, 705-710.
12. Wangler N. J., Santos K. L., Schadock I., Hagen F. K., Escher E., Bader M., Speth R. C., and, Karamyan V. T., (2012) Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site. J. Biol. Chem. 287, 114-122.